Enliven Therapeutics Inc stock is traded at $44.79, with a volume of 1,585,854. It is down -5.21% in the last 24 hours and up +5.66% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Previous Close:
$47.25
Open:
$47.10
24h Volume:
1,585,854
Relative Volume:
0.84
Market Cap:
$3.28B
Revenue:
-
Net Income/Loss:
-$98.78M
P/E Ratio:
-
EPS:
-$1.66
Net Cash Flow:
-$65.60M
1W Performance:
+1.22%
1M Performance:
+5.66%
6M Performance:
+8.71%
1Y Performance:
+144.75%
1-Day Range:
$0.00$0.00
1-Week Range:
$43.23$47.73
52-Week Range:
$14.79$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
720-647-8519Address
6200 LOOKOUT ROAD, BOULDER, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS